Canada: Pharma in Brief - Minister of Health's Decision Maintaining Import Ban on Apotex Drug Products Declared Unlawful

Case: Apotex Inc. et al v Minister of Health and Attorney General of Canada, 2016 FC 673 (Court File No. T-1653-15)

Nature of case: Application for judicial review of decision of Minister of Health

Successful party: Apotex Inc.

Date of decision: 15 June 2016


Apotex Inc., Apotex Pharmachem India Pvt Ltd. (APIPL) and Apotex Research Private Limited (ARPL) (collectively, Apotex) sought judicial review of a decision of the Minister of Health (Minister) to vary the terms and conditions of the Drug Establishment Licence (DEL) held by APIPL and ARPL (August 2015 Decision) and maintain the import ban on drugs manufactured at Apotex's APIPL and ARPL facilities.

This was the second judicial review brought by Apotex in connection with the initial import ban that Health Canada had imposed on Apotex products in September 2014. In the first judicial review (First Judicial Review), Apotex sought to have the Minister's decision to impose an import ban on Apotex quashed. The Court did so, holding that the Minister had not afforded Apotex adequate procedural fairness.

Apotex brought the second judicial review application in response to the Minister's August 2015 Decision and continued import ban on its products. In this instance, the Court held that there was no evidence to support maintaining the import ban and declared Health Canada's August 2015 Decision unlawful.  


The First Judicial Review

On September 30, 2014, following inspection reports initially conducted by the United States Food and Drug Administration noting data integrity issues at Apotex's APIPL and ARPL facilities and a subsequent inspection of the facilities by Health Canada, and in the face of media scrutiny and political pressure, an import ban was imposed on drug products coming into Canada from those facilities. Subsequently, the Minister made amendments to Apotex's DELs to prohibit the import of all products except those deemed medically necessary.

Apotex brought the First Judicial Review application to challenge the Minister's decision to implement the initial import ban and amend Apotex's DELs. The Court's decision in the First Judicial Review, dated October 14, 2015, quashed the Minister's decision to impose the import ban, finding that the import ban was motivated by an improper purpose and that Apotex was not afforded adequate procedural fairness. The Court further ordered Health Canada and the Minister to retract public statements connected to Apotex and the import ban made in the media.

The August 2015 Decision and Second Judicial Review

In the August 2015 Decision, Health Canada advised Apotex that it had further amended the terms and conditions of its DELs, requiring additional testing and reporting requirements for drug products made after June 10, 2015.

In March 2016, the Minister issued a decision removing all terms and conditions from Apotex's DELs affecting APIPL and ARPL (March 2016 Decision). However, the Minister continued to request data integrity information for Apotex's regulatory drug submissions, including for any of Apotex's Abbreviated New Drug Submissions (ANDS) where the ANDS included data generated at ARPL or APIPL prior to June 10, 2015, despite the removal of the DEL terms and conditions that required this information.

Apotex brought a second judicial review application seeking a judgment on the issue of whether the August 2015 Decision and resulting continuation of the import ban was unlawful on the basis of its connection to the decision quashed in the First Judicial Review and the evidence supporting the Minister's decision.  

Application moot

As a preliminary matter, the Minister argued that Apotex's application for review of the August 2015 decision was moot in light of the March 2016 Decision.

The Court agreed that the matter was moot, but exercised its discretion to hear the application. The Court relied, in particular, on the existence of an adversarial context between the parties, stating that an adjudication on the merits would have "collateral and practical significance on the parties' rights," including in another pending judicial review application and in an action for damages that Apotex intended to commence.  

Minister's decision unlawful and continued import ban quashed

Apotex argued that the August 2015 Decision should be quashed on the grounds that the Minister acted unlawfully in maintaining the import ban by varying the terms and conditions of the DEL in the August 2015 Decision, notwithstanding the judgment of the Court quashing the import ban in the First Judicial Review. Apotex also argued, among other things, that the Minister acted and rendered a decision that was contrary to the provisions of the Food and Drug Regulations.

The Court found that the August 2015 Decision was not independent from the 2014 import ban quashed in the First Judicial Review. The Court stated that the "two decisions are inextricably interconnected" and the facts suggest that the August 2015 Decision was not a "free-standing and uninfluenced decision, such that it was not also affected by the improper purpose that motivated the Import Ban."

On this basis, Justice Manson granted Apotex's judicial review application. He concluded that there was no evidence to justify the Minister's August 2015 Decision as a basis for maintaining the import ban, and declared the August 2015 Decision unlawful.

About Norton Rose Fulbright Canada LLP

Norton Rose Fulbright is a global law firm. We provide the world's preeminent corporations and financial institutions with a full business law service. We have 3800 lawyers and other legal staff based in more than 50 cities across Europe, the United States, Canada, Latin America, Asia, Australia, Africa, the Middle East and Central Asia.

Recognized for our industry focus, we are strong across all the key industry sectors: financial institutions; energy; infrastructure, mining and commodities; transport; technology and innovation; and life sciences and healthcare.

Wherever we are, we operate in accordance with our global business principles of quality, unity and integrity. We aim to provide the highest possible standard of legal service in each of our offices and to maintain that level of quality at every point of contact.

For more information about Norton Rose Fulbright, see

Law around the world

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on

Click to Login as an existing user or Register so you can print this article.

Similar Articles
Relevancy Powered by MondaqAI
McCarthy Tétrault LLP
In association with
Related Topics
Similar Articles
Relevancy Powered by MondaqAI
McCarthy Tétrault LLP
Related Articles
Related Video
Up-coming Events Search
Font Size:
Mondaq on Twitter
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
Email Address
Company Name
Confirm Password
Mondaq Topics -- Select your Interests
 Law Performance
 Law Practice
 Media & IT
 Real Estate
 Wealth Mgt
Asia Pacific
European Union
Latin America
Middle East
United States
Worldwide Updates
Registration (you must scroll down to set your data preferences)

Mondaq Ltd requires you to register and provide information that personally identifies you, including your content preferences, for three primary purposes (full details of Mondaq’s use of your personal data can be found in our Privacy and Cookies Notice):

  • To allow you to personalize the Mondaq websites you are visiting to show content ("Content") relevant to your interests.
  • To enable features such as password reminder, news alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our content providers ("Contributors") who contribute Content for free for your use.

Mondaq hopes that our registered users will support us in maintaining our free to view business model by consenting to our use of your personal data as described below.

Mondaq has a "free to view" business model. Our services are paid for by Contributors in exchange for Mondaq providing them with access to information about who accesses their content. Once personal data is transferred to our Contributors they become a data controller of this personal data. They use it to measure the response that their articles are receiving, as a form of market research. They may also use it to provide Mondaq users with information about their products and services.

Details of each Contributor to which your personal data will be transferred is clearly stated within the Content that you access. For full details of how this Contributor will use your personal data, you should review the Contributor’s own Privacy Notice.

Please indicate your preference below:

Yes, I am happy to support Mondaq in maintaining its free to view business model by agreeing to allow Mondaq to share my personal data with Contributors whose Content I access
No, I do not want Mondaq to share my personal data with Contributors

Also please let us know whether you are happy to receive communications promoting products and services offered by Mondaq:

Yes, I am happy to received promotional communications from Mondaq
No, please do not send me promotional communications from Mondaq
Terms & Conditions (the Website) is owned and managed by Mondaq Ltd (Mondaq). Mondaq grants you a non-exclusive, revocable licence to access the Website and associated services, such as the Mondaq News Alerts (Services), subject to and in consideration of your compliance with the following terms and conditions of use (Terms). Your use of the Website and/or Services constitutes your agreement to the Terms. Mondaq may terminate your use of the Website and Services if you are in breach of these Terms or if Mondaq decides to terminate the licence granted hereunder for any reason whatsoever.

Use of

To Use you must be: eighteen (18) years old or over; legally capable of entering into binding contracts; and not in any way prohibited by the applicable law to enter into these Terms in the jurisdiction which you are currently located.

You may use the Website as an unregistered user, however, you are required to register as a user if you wish to read the full text of the Content or to receive the Services.

You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these Terms or with the prior written consent of Mondaq. You may not use electronic or other means to extract details or information from the Content. Nor shall you extract information about users or Contributors in order to offer them any services or products.

In your use of the Website and/or Services you shall: comply with all applicable laws, regulations, directives and legislations which apply to your Use of the Website and/or Services in whatever country you are physically located including without limitation any and all consumer law, export control laws and regulations; provide to us true, correct and accurate information and promptly inform us in the event that any information that you have provided to us changes or becomes inaccurate; notify Mondaq immediately of any circumstances where you have reason to believe that any Intellectual Property Rights or any other rights of any third party may have been infringed; co-operate with reasonable security or other checks or requests for information made by Mondaq from time to time; and at all times be fully liable for the breach of any of these Terms by a third party using your login details to access the Website and/or Services

however, you shall not: do anything likely to impair, interfere with or damage or cause harm or distress to any persons, or the network; do anything that will infringe any Intellectual Property Rights or other rights of Mondaq or any third party; or use the Website, Services and/or Content otherwise than in accordance with these Terms; use any trade marks or service marks of Mondaq or the Contributors, or do anything which may be seen to take unfair advantage of the reputation and goodwill of Mondaq or the Contributors, or the Website, Services and/or Content.

Mondaq reserves the right, in its sole discretion, to take any action that it deems necessary and appropriate in the event it considers that there is a breach or threatened breach of the Terms.

Mondaq’s Rights and Obligations

Unless otherwise expressly set out to the contrary, nothing in these Terms shall serve to transfer from Mondaq to you, any Intellectual Property Rights owned by and/or licensed to Mondaq and all rights, title and interest in and to such Intellectual Property Rights will remain exclusively with Mondaq and/or its licensors.

Mondaq shall use its reasonable endeavours to make the Website and Services available to you at all times, but we cannot guarantee an uninterrupted and fault free service.

Mondaq reserves the right to make changes to the services and/or the Website or part thereof, from time to time, and we may add, remove, modify and/or vary any elements of features and functionalities of the Website or the services.

Mondaq also reserves the right from time to time to monitor your Use of the Website and/or services.


The Content is general information only. It is not intended to constitute legal advice or seek to be the complete and comprehensive statement of the law, nor is it intended to address your specific requirements or provide advice on which reliance should be placed. Mondaq and/or its Contributors and other suppliers make no representations about the suitability of the information contained in the Content for any purpose. All Content provided "as is" without warranty of any kind. Mondaq and/or its Contributors and other suppliers hereby exclude and disclaim all representations, warranties or guarantees with regard to the Content, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. To the maximum extent permitted by law, Mondaq expressly excludes all representations, warranties, obligations, and liabilities arising out of or in connection with all Content. In no event shall Mondaq and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use of the Content or performance of Mondaq’s Services.


Mondaq may alter or amend these Terms by amending them on the Website. By continuing to Use the Services and/or the Website after such amendment, you will be deemed to have accepted any amendment to these Terms.

These Terms shall be governed by and construed in accordance with the laws of England and Wales and you irrevocably submit to the exclusive jurisdiction of the courts of England and Wales to settle any dispute which may arise out of or in connection with these Terms. If you live outside the United Kingdom, English law shall apply only to the extent that English law shall not deprive you of any legal protection accorded in accordance with the law of the place where you are habitually resident ("Local Law"). In the event English law deprives you of any legal protection which is accorded to you under Local Law, then these terms shall be governed by Local Law and any dispute or claim arising out of or in connection with these Terms shall be subject to the non-exclusive jurisdiction of the courts where you are habitually resident.

You may print and keep a copy of these Terms, which form the entire agreement between you and Mondaq and supersede any other communications or advertising in respect of the Service and/or the Website.

No delay in exercising or non-exercise by you and/or Mondaq of any of its rights under or in connection with these Terms shall operate as a waiver or release of each of your or Mondaq’s right. Rather, any such waiver or release must be specifically granted in writing signed by the party granting it.

If any part of these Terms is held unenforceable, that part shall be enforced to the maximum extent permissible so as to give effect to the intent of the parties, and the Terms shall continue in full force and effect.

Mondaq shall not incur any liability to you on account of any loss or damage resulting from any delay or failure to perform all or any part of these Terms if such delay or failure is caused, in whole or in part, by events, occurrences, or causes beyond the control of Mondaq. Such events, occurrences or causes will include, without limitation, acts of God, strikes, lockouts, server and network failure, riots, acts of war, earthquakes, fire and explosions.

By clicking Register you state you have read and agree to our Terms and Conditions